Sotera Health (SHC) Projected to Post Quarterly Earnings on Tuesday

Sotera Health (NASDAQ:SHC) is expected to be announcing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of $0.17 per share and revenue of $270.7790 million for the quarter. Sotera Health has set its FY 2026 guidance at 0.930-1.01 EPS. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 9:00 AM ET.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Tuesday, February 24th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.02. Sotera Health had a net margin of 6.70% and a return on equity of 42.38%. The company had revenue of $303.44 million for the quarter, compared to analysts’ expectations of $300.68 million. During the same period in the prior year, the business earned $0.21 EPS. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. On average, analysts expect Sotera Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sotera Health Stock Down 0.6%

Sotera Health stock traded down $0.10 during midday trading on Monday, hitting $15.41. 211,289 shares of the company’s stock were exchanged, compared to its average volume of 2,464,979. The company has a market cap of $4.39 billion, a PE ratio of 57.15 and a beta of 1.82. Sotera Health has a 12 month low of $10.80 and a 12 month high of $19.85. The company has a debt-to-equity ratio of 3.66, a quick ratio of 2.24 and a current ratio of 2.46. The firm has a 50-day moving average of $15.04 and a two-hundred day moving average of $16.49.

Analysts Set New Price Targets

A number of brokerages recently commented on SHC. Wall Street Zen downgraded shares of Sotera Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 11th. Piper Sandler raised shares of Sotera Health from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $17.00 to $24.00 in a research note on Friday, January 9th. Zacks Research downgraded shares of Sotera Health from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Wells Fargo & Company downgraded shares of Sotera Health to an “overweight” rating in a research note on Thursday, January 8th. Finally, Citigroup boosted their price objective on shares of Sotera Health from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.14.

Insider Transactions at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $15.27, for a total transaction of $152,700,000.00. Following the completion of the transaction, the director directly owned 12,735,301 shares in the company, valued at $194,468,046.27. The trade was a 43.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.36% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SHC. Empowered Funds LLC lifted its position in Sotera Health by 11.1% during the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after purchasing an additional 2,845 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Sotera Health by 14.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock valued at $3,999,000 after purchasing an additional 43,471 shares during the period. Acadian Asset Management LLC lifted its position in Sotera Health by 125.5% during the first quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock valued at $293,000 after purchasing an additional 14,018 shares during the period. Creative Planning lifted its position in Sotera Health by 15.3% during the second quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after purchasing an additional 2,673 shares during the period. Finally, Invesco Ltd. lifted its position in Sotera Health by 4.2% during the second quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock valued at $3,549,000 after purchasing an additional 12,758 shares during the period. 91.03% of the stock is currently owned by institutional investors and hedge funds.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.